Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Molecular Partners AG
DescriptionDesigned ankyrin repeat protein (DARPin) that inhibits HER2 and HER3
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu) mRNA ; Erb-b2 receptor tyrosine kinase 3 (ERBB3) (HER3) (EGFR3)
Mechanism of Action 
Therapeutic ModalityBiologic
Latest Stage of DevelopmentPreclinical
Standard IndicationBreast cancer
Indication DetailsTreat HER2-positive breast cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today